SCHEMBL3263345

SCHEMBL3263345

N#CC1Cc2c(Br)cccc21

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GID4 Q8IVV7 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
DYRK1A Q13627 2/20 0.33
KDM1A O60341 1/20 0.32
PIM1 P11309 1/20 0.31
CSNK1A1 P48729 1/20 0.31
CDK5 Q00535 1/20 0.31
ROCK1 Q13464 1/20 0.31
LRRK2 Q5S007 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31
DYRK1B Q9Y463 1/20 0.31
BRD4 O60885 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20478461 0.81 GID4 (0.45) GID4KDM4EALDH1A1DYRK1AKDM1A
SCHEMBL30308765 0.81 GID4 (0.45) GID4KDM4EALDH1A1DYRK1AKDM1A
SCHEMBL768802 0.79 GID4 (0.43) GID4KDM4EALDH1A1
SCHEMBL7547848 0.78 CHRNB2 (0.44) KDM4EALDH1A1KDM1AHTR2CHTR2B
SCHEMBL1721503 0.77 TRPM5 (0.42) KDM4EALDH1A1DYRK1AKDM1AHTR2C
SCHEMBL3032214 0.73 CUL4A (0.39) HTR2CHTR2B
SCHEMBL25329492 0.73 CDK5 (0.36) GID4KDM4EALDH1A1DYRK1APIM1
SCHEMBL30576543 0.73 CDK5 (0.36) GID4KDM4EALDH1A1DYRK1APIM1
SCHEMBL7542927 0.69 LDHA (0.32) HTR2CHTR2B
SCHEMBL23053830 0.68 KDM1A (0.42) GID4KDM4EALDH1A1DYRK1AKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076325-B2 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-12-13 US disclosed
EP-2036892-B1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2010-03-10 EP disclosed
EP-2036892-A1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2009-03-18 EP disclosed
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them OXER1, NR1H3, OXSR1 GID4 2892/4885KDM4E 1558/4885ALDH1A1 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.